Wutrich 2003.

Methods	Randomised DBPC trial
Participants	Children Age range 4 to 11 years Active 14 (7 m); losses to f/u 2 Placebo 14 (9 m); losses to f/u 0
Interventions	24 months SLIT Sublingual drops Mixed grasses (Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis) Build‐up phase 30 days ‐ cumulative dose of major allergen was 1.88 mcg Maintenance phase ‐ cumulative dose of major allergen 6 mcg The first year the cumulative dose was 67.88 mcg and 139.88 mcg of major allergen in total
Outcomes	Conjunctival provocation test Skin prick test Symptom scores ‐ diary cards Medication scores ‐ diary cards
Notes	Jadad scale 5/5 4 children were not included in data analysis because of their incomplete diary cards
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Patients were randomised
Allocation concealment?	Unclear risk	No details were provided
Blinding? All outcomes	Low risk	Investigators and participants were blinded to treatment assignment for the duration of the study
Incomplete outcome data addressed? All outcomes	Low risk	Participants lost to follow up or excluded were accounted for along with patients followed to designated follow‐up periods
Free of selective reporting?	Low risk	The specified outcomes in the methodology were reported in the results section
Free of other bias?	Unclear risk	Small number of patients across each trial group

DBPC = double‐blind, placebo‐controlled; f/u= follow up; mcg = microgram; ITT = intention‐to‐treat; m = male; n/s = not specified; SCIT = subcutaneous (injection); immunotherapy; SL = sublingual; SLIT = sublingual immunotherapy; SPT = skin prick test